Rapid Method for Diagnosis of Leprosy by Measurements of Antibodies to the *M. leprae* 35-kDa Protein: Comparison with PGL-I Antibodies Detected by ELISA and “Dipstick” Methods

Paul W. Roche, Sarah S. Failbus, Warwick J. Britton, and Robert Cole

The measurement of antileprosy antibodies has been utilized as a means of detecting leprosy exposure (1,3), classifying patients with clinical disease (1,10), monitoring the response to chemotherapy (4), and defining patients at increased risk of type 1 reactions (10,11).

The 35-kD protein of *Mycobacterium leprae* is a major target for the antibody response in lepromatous leprosy (4). In the past, the only assay to detect such antibodies relied on the inhibition of the binding of a labelled monoclonal antibody to the protein present in sonicates of the leprosy bacillus (12). The 35-kD protein has recently been cloned, sequenced, and expressed as a recombinant protein in the fast-growing mycobacteria *M.* *smegmatis.* This protein retains the conformational epitope recognized by leprosy sera (14). Recent studies have shown that an enzyme-linked immunosorbent assay (ELISA) using the recombinant protein has an equivalent sensitivity and specificity to that of the monoclonal inhibition ELISA (15).

Phenolic glycolipid-I (PGL-I) is an abundant cell-surface glycolipid of *M. leprae* with a unique terminal trisaccharide (16) which is the target for a strong IgM antibody response in lepromatous leprosy patients (4).

The major drawback in the application of serology to leprosy control programs has been the need to establish a laboratory capable of performing the ELISAs. The use of dried blood samples has allowed central laboratories to collect samples for serology from widely distributed clinics. However, a rapid bedside test would clearly be preferable. The need for new leprosy diagnostics will increase as a decline in the prevalence of clinical leprosy is accompanied by a decline in the availability of other diagnostic tests, such as the slit-skin smear.

In this paper we report for the first time the use of a rapid antibody detection kit using the *M. leprae* 35-kD protein and compare this assay procedure with the standard ELISA. In addition, we compare the sensitivity and specificity for leprosy disease with that obtained using the anti-PGL-I assay as measured both by conventional ELISA and by the new “dipstick” method (2).

**MATERIALS AND METHODS**

**Patients.** A total of 174 patients and healthy controls were tested. These included 111 males and 63 females with an age range of 9 to 81 years. The study group was composed of 10 healthy Nepali persons with no known contact with leprosy or tuberculosis; 30 Nepali tuberculosis patients (16 had pulmonary disease, 11 of whom were smear positive, and 14 had nonpulmonary disease); 47 healthy contacts of leprosy patients (38 household and 9 nonhousehold contacts), and 87 leprosy patients (5 tuberculoid (TT), 31 borderline tuberculoid (BT), 2 borderline (BB), 25...
borderline lepromatous (BL), 18 lepromatous (LL) and 6 primary neuritic (PN)]. Of the leprosy patients, 50 had had no previous antileprosy treatment and 37 had had treatment of varying lengths.

**Assay 1.** IgM anti-PGL-I antibodies were measured by an ELISA as previously described (1). Briefly, wells of a microtiter tray (Dynatech, Chantilly, Virginia, U.S.A.) were coated with 100 µl of disaccharide-bovine serum albumin (d-BSA, supplied by IMMYC, World Health Organization), 250 ng/ml in 0.05 M carbonate buffer, pH 9.6, blocked with 200 µl 1% w/v BSA and incubated with patient sera diluted 1:300 in 10% normal goat serum (NGS) in phosphate buffered saline (PBS). After washing with PBS 0.05% Tween 20 (PBST), 100 µl goat anti-human IgM-peroxidase conjugate (Cappel Laboratories, West Chester, Pennsylvania, U.S.A.) diluted 1:4000 in 10% NGS/PBS was added before incubation with 100 µl 0.4 g/L o-phenylenediamine (OPD; Sigma Chemical Co., St. Louis, Missouri, U.S.A.) in 0.05 M citrate phosphate buffer, pH 5.0, containing 0.006% hydrogen peroxide. The reaction was stopped after 10 min with 100 µl of 2.5 M sulfuric acid, and the plates were read at 492 nm in a MRX microplate reader (Dynatech). Sera with an absorbance at 492 nm of greater than or equal to 0.2 (which is the mean plus 3 standard deviations of 50 Nepali healthy control sera) were considered positive.

**Assay 2.** IgG anti-35-kD antibodies were measured as previously described (13). Briefly, microtiter trays were coated with 100 µl of 10 µg/ml of the purified recombinant 35-kD protein in carbonate buffer, pH 9.6, blocked with 200 µl 1% w/v BSA and then incubated with patient sera diluted 1 in 100 in 1% BSA. After washing with PBST, 100 µl of anti-human IgG-peroxidase conjugate, diluted in 1000 in 1% BSA was added before incubation with OPD substrate for 20 min. Samples with an absorbance greater than 0.2, which was the mean of 50 Nepali healthy control sera plus 3 standard deviations, were considered positive.

**Assay 3.** Anti-35-kD cards were supplied by Amrad ICT Diagnostics, Brookvale, NSW, Australia (Fig. 1A). This consisted of a unique cardboard folder (2). The right-hand face contained a nitrocellulose (NC) strip (6 mm × 22 mm) on which the 35-kD antigen was applied (3). A control, namely, polyclonal anti-human Ig antisera (C), was applied as a positive control. At the base and top of the NC strip were thin absorbent pads (1 and 2). The left-hand face of the device had a window cut into it (5). A conjugate pad (4) was situated above the window on which 5 µl of goat anti-human IgG conjugate linked to colloidal gold was dried. There was a thick absorbent pad below the window. Two drops of buffer reagent were added to the lower pad (1) followed by an application of 30 µl of serum to the upper pad above the NC strip (2). Serum was allowed to diffuse down the NC to the marked line (L), at which point one drop of buffer was added to the transfer pad (3). At this point the folder was closed with an adhesive strip. If a patient has antibodies to the 35-kD protein, a red line will start to appear within 5 min of closing the apparatus. The final result of the test was read after 15 min.

**Assay 4.** Dipstick method. The detection of anti-PGL-I antibodies by the dipstick method was performed as previously described (2). Briefly, dipsticks had the synthetic antigen disaccharide-BSA conjugate immobilized on a NC strip. An internal control was provided by anti-human IgM antibodies immobilized in a lower band on the same NC strip. Serum was diluted 1:50 in detection reagent which was composed of a monoclonal anti-human IgM conjugated to palinal red, a colloidal dye. Detection strips were placed directly into the diluted samples after pre-wetting, incubated for 3 hr at room temperature, then rinsed, air dried and read. A reddish-stained antigen band indicated a positive reaction. Stainings of varying intensities were scored as positive: the absence of color was scored as negative.

**Statistical analysis.** The differences between groups in the proportion of subjects seropositive were tested by means of the chi-squared test. The degree of concordance between assays measuring the same antibodies by means of different assays was calculated by determining the kappa values which express agreement between methods beyond that due to chance. A kappa value of 1.0 reflects perfect agreement.

**RESULTS**

**Rapid methods.** All assays were performed by staff with considerable serologi-
Fig. 1. Diagrammatic and pictorial representation of the 35-kD test card used in this study. A = Diagram showing details of the opened device. 1. absorbent pad, 2. transfer pad, 3. serum pad, 4. conjugate pad, 5. window, T = test antigen line on nitrocellulose strip, C = control line, L = limit line to which serum is allowed to run. B = Two 35-kD test cards: one from a positive sample (LL patient, ELISA $A_{450} = 0.509$) and one from a control subject ($A_{450} = 0.1$). The internal control band is positive in both.

cal experience. Under these conditions, the 35-kD test card was found to be easy to use and generally unequivocal in the results obtained (Fig. 1B). Similarly, the PGL-I dipstick was easy to use, although there were more handling steps (pre-wetting, dispensing detection reagent, diluting serum and rinsing dipstick), the time to result was considerably longer (3 hr compared with 15 min), and some of the sera gave weak color responses.

**Comparison between ELISAs and rapid methods.** Table 1 shows the compar-
Comparisons of ELISAs and rapid methods to detect antibodies to Mycobacterium leprae 35-kD protein or M. leprae phenolic glycolipid-I.

<table>
<thead>
<tr>
<th></th>
<th>Anti 35-kD ELISA</th>
<th>Anti-PGL-I ELISA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. positive</td>
<td>No. negative</td>
</tr>
<tr>
<td>35-kD test card</td>
<td>43</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>88</td>
</tr>
<tr>
<td>Total</td>
<td>63</td>
<td>111</td>
</tr>
</tbody>
</table>

Agreement = 75.3%, chi^2 = 36.6, p <0.001; kappa value = 0.47.

Serological test results in different study groups. Table 2 shows the proportion positive for each group for each of the four assays. There were no significant differences in the proportions positive in each group as measured by ELISA compared with the rapid methods.

The PGL-I assays showed high specificity and lower sensitivity for detection of untreated leprosy compared with the 35-kD assays which had lower specificity but higher sensitivity (Table 3). There were no significant differences in the detection of untreated leprosy of any classification between rapid and standard ELISAs for either of the two antibody types. A combination of both assays, whether ELISA or rapid, led to a significant improvement in sensitivity for detecting paucibacillary (PB) leprosy with a small decrease in specificity.

DISCUSSION

This study establishes a new rapid method for detecting antileprosy antibodies by measuring antibodies to the M. leprae 35-kD protein by an immuno-chromatographic method. The concordance between the rapid method and the standard direct ELISA using the same antigen is high, although the concordance is not yet satisfactory. The sensitivity for detecting untreated PB leprosy is significantly better than that of the anti-PGL-I assays, but there is a lower specificity.

The reasons for the lower specificity of the anti-35-kD assays for leprosy are probably the result of the recombinant expression system used to produce the M. leprae
35-kD protein. As previously reported, the expression of this protein in standard *Escherichia coli* expression systems failed to produce a soluble protein and it failed to produce protein with the major antibody epitope for the monoclonal MLO4, which is also the dominant epitope for binding by leprosy sera (14). This led us to develop an expression system for this protein in the rapidly growing mycobacterium *M. smegmatis*, which yielded a “native”-like protein with the correct folding to give the antibody epitope. The protein purified by monoclonal affinity chromatography from sonicates of *M. smegmatis*, however, contains a variable amount of contaminating myco-
TABLE 2. Percentage seropositivity in study groups according to the four assays.

<table>
<thead>
<tr>
<th>Group</th>
<th>No.</th>
<th>35-kD Ab card</th>
<th>35-kD ELISA</th>
<th>PGL-1 dipstick</th>
<th>PGL-1 ELISA</th>
<th>Either ELISA positive</th>
<th>Either rapid method positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endemic controls</td>
<td>10</td>
<td>10%</td>
<td>10%</td>
<td>0%</td>
<td>0%</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Leprosy contacts</td>
<td>47</td>
<td>6%</td>
<td>19%</td>
<td>0%</td>
<td>0%</td>
<td>19%</td>
<td>6%</td>
</tr>
<tr>
<td>Tuberculosis patients</td>
<td>30</td>
<td>13%</td>
<td>6%</td>
<td>0%</td>
<td>3%</td>
<td>10%</td>
<td>13%</td>
</tr>
<tr>
<td>PB leprosy (TT/BT)</td>
<td>36</td>
<td>55%*</td>
<td>55%*</td>
<td>25%</td>
<td>22%</td>
<td>69%*</td>
<td>63%*</td>
</tr>
<tr>
<td>MB leprosy (BB, BL, LL)</td>
<td>45</td>
<td>82%*</td>
<td>62%*</td>
<td>53%*</td>
<td>60%*</td>
<td>73%*</td>
<td>86%*</td>
</tr>
<tr>
<td>PN leprosy</td>
<td>6</td>
<td>16%</td>
<td>19%</td>
<td>16%</td>
<td>16%</td>
<td>66%</td>
<td>33%</td>
</tr>
</tbody>
</table>

Significant increase in proportion seropositive compared with endemic control group: * p <0.05; ** p <0.01; *** p <0.001.

bacterial host-cell proteins to which both endemic healthy subjects as well as patients with tuberculosis may have antibodies. The amount of host-cell contamination varies from batch to batch, and this variation may explain the relatively high discordance between the 35-kD test card and the ELISA method. New expression systems in *M. smegmatis* with *M. smegmatis*-specific “tags” to allow better purification from host proteins will reduce the nonspecific antibody binding and improve the specificity of the assay.

The rapid method for detecting antibodies to PGL-1 shows a high concordance to the ELISA method (2). The PGL-1 antibodies, however, are detectable in a lower proportion of PB leprosy patients than the anti-35-kD antibodies, whether measured by the methods shown here or by the monoclonal inhibition assay (2). The combination of the two assays significantly improves the detection of untreated PB leprosy. Further, the rapid assay methods could in the future be combined to allow the simultaneous detection of both anti-35-kD and anti-PGL-1 antibodies in the same sample. In addition, both assays are adaptable to the use of whole blood in the place of serum, further simplifying the procedure and making the field application of the test(s) more feasible.

As registered leprosy prevalence continues to decline, skills and experience necessary for the diagnosis of the disease will become more rare. In countries with a low leprosy prevalence, new technologies like the ones described in this paper will be needed to allow the timely diagnosis of leprosy.

**SUMMARY**

A new rapid immuno-chromatographic test card for the detection of antibodies to the *Mycobacterium leprae* 35-kD protein is described. The new assay is compared in the same group of subjects with a direct enzyme ELISA method for 35-kD antibodies and with assays for anti-phenolic glycolipid-1 (PGL-1) antibodies using a standard ELISA as well as the recently described “dipstick” method. Good concordance was found between the rapid methods and the corresponding ELISA methods. The detection of untreated paucibacillary leprosy by the 35-kD test card was 59% compared...

**TABLE 3. Sensitivity and specificity for each assay used in the study.**

<table>
<thead>
<tr>
<th>Specificity to:</th>
<th>35-kD Ab card</th>
<th>35-kD ELISA</th>
<th>PGL-1 dipstick</th>
<th>PGL-1 ELISA</th>
<th>Either ELISA positive</th>
<th>Either rapid method positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endemic controls</td>
<td>90%</td>
<td>90%</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>Leprosy cpf TB</td>
<td>80%</td>
<td>93%</td>
<td>100%</td>
<td>97%</td>
<td>90%</td>
<td>87%</td>
</tr>
<tr>
<td>Sensitivity* for:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PB leprosy</td>
<td>59%</td>
<td>50%</td>
<td>27%</td>
<td>23%</td>
<td>63%</td>
<td>63%</td>
</tr>
<tr>
<td>MB leprosy</td>
<td>84%</td>
<td>72%</td>
<td>64%</td>
<td>68%</td>
<td>80%</td>
<td>88%</td>
</tr>
</tbody>
</table>

* cpf = compared with.
** For untreated disease.
with 27% for the PGL-I dipstick; however, the specificity for the 35-kD test card was 90% compared with 100% for the PGL-I dipstick in an endemic population. The potential application of these new, rapid serological methods for the diagnosis of leprosy under field conditions is discussed.

RESUMEN

Se describe una nueva y rápida prueba inmunocromatográfica en tarjeta para la detección de antisueros contra la proteína de 35 kDa de Mycobacterium leprae. El ensayo se compara en el mismo grupo de sujetos con una prueba de ELISA para el mismo antígeno y con dos ensayos para el glicolipido fenólico-I (PGL-I): un ELISA y la recientemente descrita prueba de la tira reactiva. Se encontró una buena concordancia entre las pruebas rápidas y los ELISAs correspondientes. La detección de pacientes paucibacilares usando la prueba de la tarjeta para la proteína de 35 kD fue del 95% comparada con el 27% para la prueba de la tira reactiva para el PGL-I; sin embargo, la especificidad para la prueba de la tarjeta (35 kD) fue del 90% comparada con el 100% para la tira reactiva (PGL-I) en una población endémica. Se discute la aplicación potencial de estos nuevos métodos serológicos rápidos en el diagnóstico de la lepra bajo condiciones de campo.

RÉSUMÉ

Un nouveau test rapide immuno-chromatographique sur cartes, pour la détection d’anticorps dirigés contre la protéine de 35 kDa de Mycobacterium leprae est présenté. Cette nouvelle méthode est comparée chez le même groupe de sujets avec un test direct de type ELISA mesurant les anticorps contre la protéine de 35 kDa, et des tests mesurant les anticorps contre le glicolipide phénolique de type 1 (PGL-I) utilisant une méthode ELISA standard, ainsi que la méthode récemment décrite dite de la bandelette (dipstick). Une bonne concordance fut trouvée entre les méthodes rapides et les méthodes ELISA correspondantes. La détection des cas non-traités de lépre paucibacillaire par le test sur carton de la protéine de 35 kDa était de 59% comparé à 27% pour le PGL-I par la bandelette; cependant, la spécificité du test sur carton de la protéine de 35 kDa était de 90% comparé à 100% pour le PGL-I par la bandelette dans une population endémique. Les applications potentielles de ces nouvelles méthodes sérologiques rapides pour le diagnostic de la lépre sur le terrain sont discutées.

Acknowledgment. This work was supported by The Leprosy Mission International. The authors would like to thank the staff and patients of Anandaban Hospital for their cooperation in this study. We thank Dr. Paul Klatser and Dr. Samira Buhrer, Department of Biomedical Science, Royal Tropical Institute, Amsterdam, The Netherlands, for supplying the PGL-I antibody dipsticks for this study and for their valuable suggestions on the manuscript. This work was presented as a poster at the International Leprosy Congress, Beijing, China September 7-12, 1998 (Abstract no: IM59).

REFERENCES


